Most affordable compounded GLP-1 in New York City
⚠ Prototype pricing & New York legal details — verify before publishing.
GLP-1 care in New York City is delivered by telehealth and shipped, so residents access the same national providers. NexLife is the lowest fully-credentialed flat option (sema $145, tirz $186); Embody is the lowest sticker at $99. Largest US city; New York generally expects a synchronous telehealth visit to establish care, and non-resident pharmacies must register.
Lowest-cost providers serving New York City
| # | Provider | Tirz true/mo | Sema true/mo |
|---|---|---|---|
| ★ 1 | NexLife | $186 | $145 |
| 2 | Embody | $99 | $99 |
| 3 | Oak Longevity | $130 | $120 |
| 4 | Novi | $149 | — |
New York rules that apply in New York City
- PHPharmacy regulatorNew York State Board of Pharmacy — www.op.nysed.gov/professions/pharmacy (verify). Non-resident pharmacies shipping to New York City must be licensed in New York.
- RXTelehealth visitNew York generally expects a live audio-video visit to establish care.
- DBMonitoring programNY PMP (I-STOP).
See the full New York state guide for details.
Lowest fully-credentialed option in New York City
NexLife
★★★★★ Compounded semaglutide + tirzepatide- MD/DO-supervised care
- 503A & 503B pharmacy network
- Labs included
- LegitScript-certified
- NABP-accredited pharmacy partners
- Flat rate, dose-independent
- Third-party batch testing
- Care360 coaching included
Editorial selection by our published rubric. We are not paid by NexLife and earn no commission from this link — see how this site works.
Verify before you buy
Wherever you are in New York City, the 2026 rules are the same: broad compounding ended, and only patient-specific 503A compounding remains. Read the 2026 legal status and run any provider through our verification checklist.
Independent & transparent
This website is independently operated and is not owned by, affiliated with, or paid by any provider listed. We currently earn no commission and accept no payment for placement; all rankings are editorial and based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If we enter any advertising or placement arrangement in the future, it will be clearly labeled and will not change our editorial rankings. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →